Topic Archives: Pfizer (PFE)

“Rising Healthcare Demand Enables 100+ Year Dividend-Paying Pharma Giant to Enter Best Dividend Stocks List”

Every now and then a reader sends in a question about one of the stock ideas teased by dividend.com, which is a service that looks for, you guessed it, dividend paying stocks. Their standard “tease” is that they send around some hints about the latest stock they’ve added to one of their “best” lists, but […]

Conflict Diamonds

[Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trade restrictions, chooses his own topics, and his words and opinions are his own. You can see all his past articles and more recent comments here.] Picture the gurbling fumaroles of Yellowstone: from the late 1990’s and on into […]

The Tao of Recro

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. You can see all of his past articles here.] “Who wants honey? As long as there’s some money?” —–“Cherub Rock,” Smashing Pumpkins, Siamese Dream (words and […]

The Long Case for Receptos

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Gumshoe Irregulars. He has agreed to our trading restrictions, he chooses his own topics, and his words and opinions are his own. Enjoy!] OK, admit it….how many of you have seen the campy films of Baltimore director John Waters? The ones starring the […]

Payola from Portola?

In his tearjerker “Sisters of Mercy,” Leonard Cohen sings, I’ve been where you’re hanging and think I can see how you’re pinned. Although I am less inclined to bash the FDA than many, it has recently let modern medical practice place many patients in an undesirable situation. What if there was a very powerful drug, […]

Special Update on Cellceutix

[ed. note: Dr. KSS writes about biotech stocks for the Irregulars. He has agreed to our trading restrictions, but he chooses his own topics and his words and thoughts are his own] According to new SEC filings, Cellceutix President, co-founder and Chief Scientific Officer Krishna Menon has recently settled what should probably be regarded as […]

A Non-Statin Pill That Really Lowers Cholesterol, Blood Pressure and Inflammation without Side Effects Would be a Good Investment, Right?

[Ed. Note: Dr. KSS writes about medical topics and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his thoughts and words are his own. Enjoy!] Any discussion of cholesterol immediately turns Brobdingnagian, such are the extremes in question. Statins, which lower LDL cholesterol, are bombastically the best-selling drugs of all […]

Hepatitis with a C

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. His words and opinions are his own.] In A History of New York, Washington Irving opens chapter VIII thus: ”In which the author and reader…fall into a very grave and instructive discourse.” This may prove to be a more unleavened column than […]

Comments

  • Avatar

    Travis ---you're right on-----The five he talks about are: ABBV, PFE, JNJ, MRK amd UNH...

  • Travis Johnson, Stock Gumshoe

    FYI: Pfizer earnings were fine, but the guidance for 2019 earnings was lower than analyst estimates (thanks to the stron...

  • Avatar

    Who knows if any of what Shousen says is true but I'm in PFE just because it's a good company and pays a nice dividend. ...

  • Avatar

    Switzerland is divided in three main region where we speak French, German and italian (plus grischun) hence the swiss-it...

  • Avatar

    It's more likely PFE would buy out $AMRN by the end of 2019, and that, folks, would be 100% easy from current levels....

  • Avatar

    It is Italian but operates its partnerships out of Switzerland and has linked up with lots of drug firms besides PFE inc...

  • Avatar

    It is Italian but operates its partnerships out of Switzerland and has linked up with lots of drug firms besides PFE inc...

  • Avatar

    I'll stick to investing in my brother. He's worked for 3 companies that have been acquired by PFE. He stayed for awhil...

  • Travis Johnson, Stock Gumshoe

    That’s one of Jimmy Mengel’s recent teases, most of it is a rehash of previous pitches but that new addition of the ...

  • Avatar

    $AKAO Just finished reading the whole transcript of the Conference Call which I would suggest others do, time permitting...

  • Avatar

    Kiplinger makes a case for Pfizer (PFE) in your retirement account. http://www.kiplinger.com/slideshow/investing/T052-S...

  • Avatar

    For those that hold Pfizer (PFE) a good read. http://marketrealist.com/2016/11/pfizers-valuation-compared-to-peers/ ...

  • Avatar

    Pfizer (PFE) launching first mAb copycat at a small discount. http://endpts.com/pfizer-launches-first-us-mab-biosimil...

  • Avatar

    Joe, just wanted to note a couple of basics (and forgive me if you already know these): Do not use stock price as an in...

  • Dr. KSS MD PhD

    Incyte $INCY looks like a worthy alluring takeover candidate here to me. I suspect it's on a shopping list at both Aller...

  • Avatar

    Pfizer (PFE) blocking its drugs for lethal injections. https://www.yahoo.com/news/pfizer-says-blocking-drugs-lethal-i...

  • sogiam

    Pfizer (PFE) receives a large injection worth of calls. http://www.bottarelliresearch.com/trades/2016/01/28/pfizer-rece...

  • Avatar

    Pfizer (PFE) receives a large injection worth of calls. http://www.bottarelliresearch.com/trades/2016/01/28/pfizer-rece...

  • Avatar

    Pfizer (PFE) with 5 buy ratings in December. http://www.marketbeat.com/stocks/NYSE/PFE/ Cheers,Glenn...

  • Avatar

    Pfizer (PFE) mentioned being dirt cheap in overbought market. http://investorplace.com/2015/11/6-dirt-cheap-stocks-to-b...

  • Avatar

    Good news for Pfizer (PFE) today. http://fda.einnews.com/article/292317732/CSbRUhc0UqlsuELq Cheers,Glenn...

  • Avatar

    Pfizer (PFE) Spends $300 Million on Exploring Possibility of Split http://www.google.ca/url?sa=t&rct=j&q=&esrc=s&sourc...

  • Avatar

    An intersting point of view for you all: May 22, 2015, 1:12 P.M. ET Esperion Therapeutics: 15 Reasons to Take Profit...

  • Avatar

    Was this what the Dr. was forseeing? Introducing PfizerKline: Analyst Makes New Case for Merger of GlaxoSmithKline (GSK...

  • Avatar

    Pfizer (PFE) to make a play on Shire plc ? http://www.nasdaq.com/article/could-this-dark-horse-be-pfizer-incs-next-majo...

  • Avatar

    Well here's another M&A rumor from SA regarding PFE... -According to Reuters, Pfizer (PFE +0.2%) is negotiating a tak...

  • Avatar

    For those of you either owning or considering big Pharma companies here is an article on Patent Expiration for you to co...

  • Jim Skelton,

    I promised those of you that asked I'd get back here and tell you what are the three stocks I have a bead on to buy with...

  • Avatar

    By October 3, 2013, the U.S. Food and Drug Administration (FDA) will decide whether to approve Ligand Pharmaceutical's (...

  • Avatar

    Entfor drips there is pfizer pfe its a guarenteed winner thouh not in the near future w// the money they have and experi...

  • This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.

    Connect with Travis

    website designed by Gravity Switch